Victrex plc Declares Special Dividend As The Cash Piles Up

Victrex plc (LON VCT) reports another great year with growth across the board.

Zach Coffell

Zach’s investment career began on his 20th birthday when his father gave him a copy of The Intelligent Investor, by Benjamin Graham, and the Fool.co.uk website address! He believes in buying quality companies with durable competitive advantages and his ideal holding period is forever. Zach owns shares in: boohoo.com (LSE: BOO), Craneware (LSE: CRW), GlaxoSmithKline (LSE: GSK), Judges Scienfitic (LSE: JDG), PZ Cussons (LSE: PZC), Somero (LSE: SOM)

Published 9 December, 2014 10:51 am GMT

| More on: VCT

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Shares in speciality chemicals firm Victrex plc (LSE: VCT) jumped 4% in early trading after it reported 9% profit before tax growth in 2014.

Revenue grew 14% over the period, but margins dropped 200 basis points after the average selling price of goods fell from £76.00/kg in 2013 to £71.1/kg. Management attributed the margin erosion to higher manufacturing costs, currency impact and a softer sales mix including growth in the lower-priced Consumer Electronic business.

The outperforming PEEK resin business drove growth in the first half of the year, while new business in Consumer Electronics enhanced second half results.

Victrex also reported an increase in PEEK manufacturing capacity utilisation. At year end capacity was 78%, compared to 62% last year. Management believe this capacity utilisation increase justifies the ongoing investments into “new manufacturing assets which will support the breadth of new and larger business opportunities”.

The Invibio medical business returned to 5% growth in 2014. This reflects the continued improvement in sales to the spine market in the US, Europe and in emerging countries. Sales grew fastest in China, where Invibio experienced double digit growth.

Victrex said it will renew its focus on cost of manufacture in 2015, with the aim of improving medium term efficiency as manufacturing capacity grows. In order to support ongoing success management spent £15.7m on R&D.

The company boasts a solid balance sheet with no debt and a £89.6m cash pile. As a result of the strong cash position, management proposed a special dividend of 50p per share alongside the final dividend of 33.76p.

Looking forward, management expect volume growth to continue into the first half of 2015. The dividend is covered 2.1x by earnings, and management plan to maintain cover at a similar level.